Adlai Nortye Ltd. (ANL) Fair Value 2026

ANL · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

1.7 /10

32 fundamental signals · 9 models active

Value Trap Risk

SAFE (12/100)

Quick Summary — As of 2026-07-13, Adlai Nortye Ltd. (ANL) trades at $9.24, approximately 275% above CirclFi’s Bayesian DCF fair value of $2.46. QOC: 1.7/10. Value Trap Risk: 12/100 (SAFE). 9/13 models active.

Key Facts

Ticker
ANL
Price
$9.24
Quality Score
1.7/10
Value Trap Risk
12/100
Models Active
9/13
Last Updated
Strength: First Chicago suggests +169.6% upside with 3% confidence
Risk: Below-average Quality Score of 1.7/10 signals weak fundamentals

Valuation Matrix

9 Intrinsic Value Models vs. Current Price ($9.24)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
$2.46 -73.4%
CUCE Ensemble
Low Conviction
$6.24 -32.4%
First Chicago
Low Conviction
$24.91 +169.6%
PWERM
Low Conviction
$9.11 -1.4%

Unlock the Full Matrix

Access 5 additional models including ML-RIV, Dynamic NAV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 9 Models →

Cancel anytime · No contracts · Instant access

What Is Adlai Nortye Ltd. (ANL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Adlai Nortye Ltd. at its current price of $9.24. The composite intrinsic value is estimated at $7.42 (-19.7% average return), with 6 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $24.91 (+169.6%), while Regime Cross — the most conservative — estimates $0.27 (-97.0%). This +266.7% gap reflects genuine analytical uncertainty about Adlai Nortye Ltd.'s intrinsic worth.

What Do the Models Say About ANL?

9 of 13 models are currently active for ANL. Of these, 2 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates ANL's intrinsic value at $2.46, implying -73.4% downside from the current price. See which stocks rank higher →

How Does ANL Rank in Biotechnology?

Among 62 Biotechnology stocks, ANL ranks #62 by Quality of Company score. CirclFi's QOC score of 1.7/10 evaluates 32 fundamental signals. A score of 1.7 signals below-average fundamentals.

See all Most Undervalued Biotechnology Stocks →

Within the Biotechnology space, Adlai Nortye Ltd. competes in an environment where partnership revenue often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is ANL a Value Trap?

CirclFi's Value Trap algorithm assigns ANL a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

9 of 13 models are active for Adlai Nortye Ltd.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Adlai Nortye Ltd.'s fundamental quality profile registers 1.7/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +266.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ANL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ANL's 9 active models, average confidence is 5%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Adlai Nortye Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

8 related Biotechnology stocks with 13-model coverage

Read investment analysis: ADMA · ACAD · ALNY · ACRS · ABCL

See all Biotechnology stocks ranked →

Frequently Asked Questions About Adlai Nortye Ltd.

What is Adlai Nortye Ltd.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Adlai Nortye Ltd. (ANL) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $2.46. The Quality of Company score is 1.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ANL overvalued or undervalued right now?

At $9.24, 2 of 9 active models suggest ANL may be undervalued, while 7 indicate potential overvaluation. The assessment depends on which methodology best fits Adlai Nortye Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 1.7 mean for ANL?

Adlai Nortye Ltd.'s QOC of 1.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on ANL?

CirclFi analyzes ANL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 9 of 13 are active for this stock. Read the full methodology →

Is ANL a value trap in 2026?

Adlai Nortye Ltd.'s Value Trap score is 12/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 9 mathematical frameworks give you clarity on ANL.

Unlock All 9 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access